Phase 3 work focuses heavily on the dominant KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → pathway. Daraxonrasib (RMC-6236), a pan-RAS inhibitor, is in Phase 3 in previously treated metastatic PDAC. BMS-986504 added to gemcitabine plus nab-paclitaxel is being compared against placebo in untreated metastatic disease. The Phase 2 APOLLO trial tests olaparib maintenance after curative-intent therapy in patients with resected PDAC and pathogenic BRCA1Genes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation →, BRCA2Genes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation →, or PALB2 mutationsA change in DNA sequence that can drive cancer development.Click for full explanation →. Earlier work includes BNT327 (pumitamig), a PD-L1 and VEGF bispecific, with chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →; pegcetacoplan added to modified FOLFIRINOX; the MK2 inhibitor zunsemetinib with mFOLFIRINOX; and CA-4948 added to standard chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →. Theranostic radioligand pairs targeting integrins and somatostatin receptors are in early study, and ASP2138 for claudin 18.2-positive disease is in Phase 1. Cachexia, a major source of decline, is being addressed in trials of ponsegromab and nano-megestrol acetate. Laboratory work is uncovering KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12D inhibitor resistance through Fra-2, KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12R-specific signaling vulnerabilities, immunosuppressive damage-associated macrophages targetable via GPR34, hypoxia-driven IL-6 from fibroblasts, and tumor-reactive T-cell repertoires that may inform future immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation →.
Where the evidence stands
Combination chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → regimens remain the standard and have been incrementally improved over the last decade. PARP maintenance for BRCAGenes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation → carriers and immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → for the rare MMR-deficient subgroup are established. Pan-KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → and KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12D inhibitors are the most-watched late-stage developments. Most other novel approaches, including immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → combinations, ADCs, radioligands, and stromal-targeted strategies, are in Phase 1 or 2. Cachexia drugs are advancing in mid-stage trials. Most laboratory findings remain years from the clinic.
What this means for people affected
Pancreatic cancer remains a field where standard chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → is the foundation and new treatments have not yet substantially shifted survival for most people. The exceptions are biomarkerA measurable biological signal used to detect disease or predict treatment response.Click for full explanation →-defined subgroups: BRCAGenes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation →, PALB2, MSI-high, NTRK or NRG1 fusion, and KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12C. Comprehensive molecular profiling, including germline testing, is reasonable at diagnosis of advanced disease because it occasionally identifies these treatable groups. The recent KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation →-directed Phase 3 programs are the most consequential trials in the field, and clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → enrollment is recommended in many guidelines because standard options remain limited. Supportive care for cachexia, pain, and symptom burden is an active research area and a meaningful part of treatment.
Last updated May 1, 2026
Recent research findings
Understanding evidence levels▼
PreclinicalLab or cell studies — no human data yet.
Animal StudyResults in animals only — may not apply to humans.
Phase 1 TrialFirst-in-human safety testing in small groups.
Phase 2 TrialEarly effectiveness testing in a larger group.
Phase 3 TrialLarge controlled trial — the strongest trial evidence.
Observational StudyPatterns observed in populations — not a controlled trial.
ReviewSummary analysis of multiple existing studies.
Meta-AnalysisStatistical pooling of results from multiple studies.
Phase 1 TrialFirst-in-human trial. Focuses on safety and dosing in small groups.Est. completion: May 30, 2027
Testing a New Combination Treatment for Advanced Pancreatic Cancer
Researchers are studying a combination of three medications - Regorafenib, Toripalimab, and Albumin-bound Paclitaxel - as a potential treatment for people with advanced pancreatic cancer who have not responded to previous treatments. This trial is currently recruiting participants. The goal is to see if this combination is safe and effective.
Why it matters: This trial may help doctors find a more effective treatment option for people with advanced pancreatic cancer.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: May 15, 2026
CRISPR Gene Editing Shows Promise in Treating Pancreatic Cancer
Researchers used a gene editing tool called CRISPR to create DNA damage in pancreatic cancer cells. This caused the cells to become unstable and eventually die. The study suggests that this approach may be a new way to treat pancreatic cancer.
Why it matters: This finding could lead to new treatment options for pancreatic cancer, which is a difficult disease to manage.
The study was conducted in a lab setting and has not been tested in humans.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: May 13, 2026
Researchers Identify Natural Compounds That May Help Target Pancreatic Cancer MutationA change in DNA sequence that can drive cancer development.Click for full explanation →
Researchers used computer simulations and lab experiments to find two natural compounds, mangiferin and hesperetin 7-O-glucoside, that may be able to target a common mutationA change in DNA sequence that can drive cancer development.Click for full explanation → in pancreatic cancer cells. These compounds showed promise in lab experiments, but more research is needed to confirm their effectiveness. The study suggests that these compounds may have potential as a new treatment for pancreatic cancer.
Why it matters: This finding could lead to new treatment options for patients with pancreatic cancer, a disease that is often difficult to treat.
Efficacy
Molecular dynamics simulations demonstrated that mangiferin and hesperetin 7-O-glucoside formed stable complexes, with mangiferin showing a binding affinity of -37.04 kcal/mol and hesperetin 7-O-glucoside showing a binding affinity of -21.15 kcal/mol.
The study was conducted in lab experiments and has not yet been tested in humans.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: May 13, 2026
Pancreatic Cancer Cells Cooperate to Grow
Researchers studied how pancreatic cancer cells interact with each other in lab experiments. They found that these cells work together to create a system that helps them grow, but the details of this system are complex and not fully understood. This system involves a signaling pathway called Wnt.
Why it matters: This finding could help scientists understand how pancreatic cancer grows and develop new treatments targeting the Wnt pathway.
The study was conducted in lab experiments, and its findings may not directly apply to human patients.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: May 13, 2026
Targeted Protein Degradation in Cancer Cells
Researchers created tools to selectively remove a protein called USP7 from cancer cells. They compared the effects of removing this protein using different methods and found that it affects different proteins in different ways. The study suggests that this approach could help us understand how USP7 contributes to cancer.
Why it matters: This finding could help us better understand the role of USP7 in cancer and potentially lead to new treatments.
The study was conducted in lab experiments using melanoma and pancreatic cancer cells.
ReviewSummary and analysis of existing published studies.Published: May 13, 2026
Pancreatic Cancer in Africa: Late Diagnosis and Limited Treatment Options
Researchers looked at data on pancreatic cancer in African countries and found that most patients are diagnosed at a late stage. This makes it harder to treat and leads to poor survival rates. The study highlights the need for better diagnostic tools and treatment options.
Why it matters: This finding highlights the challenges of treating pancreatic cancer in Africa and the need for improved healthcare infrastructure.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: May 13, 2026
Rare and Aggressive Pancreatic Cancer Spread
Researchers described a case of a man with pancreatic cancer who developed a rare and aggressive form of the disease, called 'flash carcinomatosis', where the cancer spread quickly throughout his abdomen. The researchers found a specific genetic mutationA change in DNA sequence that can drive cancer development.Click for full explanation → and loss of a tumor suppressor gene in this case. This case highlights a rare and aggressive form of pancreatic cancer.
Why it matters: This finding may help researchers understand the biology of aggressive pancreatic cancer and potentially inform future research into its causes and progression.
Phase 1 TrialFirst-in-human trial. Focuses on safety and dosing in small groups.Est. completion: December 1, 2028
Testing a New Treatment for Advanced Cancers
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying a new treatment called DSB2455 for people with advanced cancers that have a specific genetic characteristic. The trial is currently recruiting participants. The goal is to assess the safety, tolerability, and effectiveness of this treatment.
Why it matters: This trial may help identify a new treatment option for people with advanced cancers that have not responded to other treatments.
Recruiting participants, early stage trial with limited data available.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: May 12, 2026
New Cancer Treatment Approach Shows Promise in Lab Experiments
Researchers used a special virus to deliver a signal that tricks the immune system into attacking pancreatic cancer cells. They found that this approach can make tumors more responsive to other treatments and even create long-lasting immunity against cancer.
Why it matters: This finding could lead to new ways to treat pancreatic cancer, which is often difficult to treat.
This study was conducted in lab experiments and animal models, and more research is needed to confirm its effectiveness in humans.
PreclinicalLab or cell studies. No human data yet.Est. completion: September 1, 2026
Evaluating a Digital Support Program for Newly Diagnosed Pancreatic Cancer Patients
This trial is studying a digital support program led by community health workers for people newly diagnosed with pancreatic cancer. The program is being compared to usual care with an attention control. The trial is currently recruiting participants.
Why it matters: This trial aims to understand whether a digitally enhanced support program can help newly diagnosed pancreatic cancer patients.
The trial is recruiting participants and its current phase is not specified.
Phase 2 TrialTests early effectiveness in a larger group after phase 1 safety is established.Est. completion: December 31, 2030
Evaluating Saltikva for Metastatic Pancreatic Cancer
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying a treatment called Saltikva for people with metastatic pancreatic cancer. Researchers are comparing Saltikva to two standard treatments. The trial is currently active but not recruiting new participants.
Why it matters: This trial aims to gather more information about the effectiveness of Saltikva in treating metastatic pancreatic cancer.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: May 9, 2026
Gastrointestinal Cancer Trends in Egypt
Researchers at a hospital in Alexandria, Egypt, looked at cancer cases over 10 years to see how often gastrointestinal cancers occurred and if the number of cases changed over time. They found that gastrointestinal cancers made up a significant portion of all cancers, but the number of cases didn't change much over the decade. However, they did see a decline in small intestinal cancer cases.
Why it matters: This study highlights the importance of understanding cancer trends in specific regions to inform future research and healthcare planning.
A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1Genes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation →, BRCA2Genes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation → or PALB2 MutationA change in DNA sequence that can drive cancer development.Click for full explanation →
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX ChemotherapiesDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →, in People With Pancreatic Cancer
